Market Overview

Hapoalim Cutting Ocverage On Multitude Of Names


Hapoalim Securities announced it would be terminating coverage of a slew of pharmaceutical names due to an analyst departure.

The names affected are Bristol-Myers (NYSE: BMY), Eli Lilly (NYSE: LLY) Merck (NYSE: MRK) Pfizer (NYSE: PFE) Acorda (NASDAQ: ACOR), Alkermes (NASDAQ: ALKS) Amarin (NASDAQ: AMRN) Amylin (NASDAQ: AMLN) Arena Pharmaceuticals (NASDAQ: ARNA), Auxilium (NASDAQ: AUXL), Biospecifics (NASDAQ: BSTC), Cephalon (NASDAQ: CEPH), MannKind (NASDAQ: MNKD), Medivation (NASDAQ: MDVN), Nektar (NASDAQ: NKTR), Neurocrine Biosciences (NASDAQ: NBIX), Protalix (NYSE: PLX) Targacept (NASDAQ: TRGT), and Vanda Pharmaceuticals (NASDAQ: VNDA).


Related Articles (ACOR + ALKS)

View Comments and Join the Discussion!

Posted-In: Hapoalim SecuritiesAnalyst Color Analyst Ratings

Latest Ratings

MRTXHC Wainwright & Co.Maintains257.0
NVDATruist SecuritiesMaintains672.0
BLKBMO CapitalMaintains715.0
BLKDeutsche BankMaintains838.0
View the Latest Analytics Ratings
Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at